US-based Avara Pharmaceutical Services has signed an asset purchase agreement to acquire Novartis Technical Operations’ sterile manufacturing facility for injectable medicines in Quebec, Canada.

The deal also covers the nearby Sandoz Development Center situated on the Sandoz Canada campus in Boucherville.

Said to be the biggest injectables production facility in Canada, the site supplies multiple drugs across the country’s healthcare system, primarily hospitals.

Avara is planning to invest in the facility and work on business development opportunities in order to optimise the site’s utilisation and boost its customer base.

The company noted that employees may not be impacted by the move.

Avara Pharmaceutical Services chairman and CEO Timothy Tyson said: “This acquisition represents our first entry into the Canadian market and further expands our sterile processing capability, which is in very high demand.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“This further expands our sterile processing capability, which is in very high demand.”

“It comes with a world-class development centre and a dedicated team of experts that will support us in delivering high-quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements.”

As part of the deal, the partners have revealed plans for a long-term supply contract aimed at uninterrupted product supply.

Financial details of the agreement have not been disclosed. The acquisition is subject to closing conditions and expected to be finalised over the coming months.

Last year, Avara purchased Pfizer’s sterile plant located in Liscate, Italy, along with a solid dose manufacturing site in Aiken, South Carolina, US, from GlaxoSmithKline.

The latest deal with Novartis brings the number of manufacturing and development sites operated by Avara to a total of ten, with two in Canada, three in the US, and one each in the UK, Ireland, France, Italy, and Puerto Rico.